Trial Profile

MTX-474-S101: A Phase 1 Randomized, Double-Blind, Dose-Escalating Study to Assess the Safety, Tolerability, and Pharmacokinetics of MTX-474 in Healthy Adults

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 09 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MTX-474 (Primary)
Indications Fibrosis
Focus Adverse reactions; First in man; Pharmacokinetics
Sponsors Mediar Therapeutics

Most Recent Events

07 Aug 2024 According to a Mediar Therapeutics media release, company announced the first cohort of participants has been dosed in a Phase 1 trial evaluating the safety and tolerability of MTX-474.
02 Aug 2024 Status changed from planning to recruiting.
06 May 2024 According to a Mediar Therapeutics media release, initiation of this Phase 1 study is anticipated in Q3-2024.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com